Medarex' Promising Cancer Products
Medarex is to commence Phase II clinical trials in Sweden with its bispecific agent MDX-210 in colon cancer patients. The company has also reported Phase II data with its leukemia drug.
MDX-210, which is being jointly developed with Ciba-Geigy, is also in Phase II trials in prostate cancer patients and has undergone Phase I/II testing in a range of tumors in the USA and Europe. The latest trial is designed to determine efficacy and to expand safety data.
Phase II Data With MDX-22 Meantime, MDX-22, Medarex' leukemia product, has continued to demonstrate long-term disease-free survival in patients with acute myeloid leukemia, according to Phase II results presented at the American Society of Hematology annual meeting in Florida, USA, recently.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze